GlassScriptPhysician profile
Amber V Bailey
NPI 1528410305
$1,190.79
in general payments reported to CMS, 2019-2025
11 companies · $699 in 2025
The $699 reported for 2025 was more than what 85% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $218 · 2024: $274 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $471.12 | 2023-2025 | Nvm5, Reline, Excelsiusgps Robotic Navigation System |
| Medtronic, INC. | $248.16 | 2025 | Atlantis Anterior Cervical Plate System, O-Arm, Endoskeleton Tc Nanolock Surface Technology |
| Ucb, INC. | $115.77 | 2024-2025 | Briviact, Fintepla, Zilbrysq |
| Integra Lifesciences Corporation | $104.09 | 2023 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Certas |
| Stryker Corporation | $91.64 | 2025 | Nico Myriad |
| Boston Scientific Corporation | $37.20 | 2024-2025 | Cds - Mct/Cem Monitoring |
| Kerecis Limited | $31.93 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Biogen, INC. | $30.53 | 2025 | Vumerity, Tysabri |
| Argenx US, INC. | $26.20 | 2025 | Vyvgart Hytrulo |
| Alon Medical Technology | $20.70 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.45 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.